ZNF385A and liver cancer: By performing TIDE analyses and survival analyses in one liver cancer and one urothelial cancer cohort receiving anti-PD-1/anti-PD-L1 therapy, we observed that ZNF385A and ZNF346 performed well in predicting the responses to ICI therapy (Figure 8).